The pathophysiology of hereditary angioedema

被引:189
作者
Davis, AE [1 ]
机构
[1] Harvard Univ, Sch Med, CBR Inst Biomed Res, Dept Pediat, Boston, MA 02115 USA
关键词
hereditary angioedema; C1; inhibitor; mucosa;
D O I
10.1016/j.clim.2004.05.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE), characterized by recurrent episodes of angioedema involving the skin. or the mucosa of the upper respiratory or the gastrointestinal tracts, results from heterozygosity for deficiency of the serine proteinase inhibitor (serpin). C1 inhibitor (C1INH). The primary biological role of C1INH is to regulate activation of the complement system, the contact system, and the intrinsic coagulation system. Dining attacks of angioedema, together with decreasing levels of C1INH, the complement and contact system are activated: C2 and C4 levels fall and high molecular weight kininogen is cleaved. Although previous data suggested that symptoms in HAE might be mediated via complement system activation, a combination of recent clinical data, in vitro studies, and analysis of C1INH-deficient mice all indicate that the major mediator of angioedema is bradykinin: (1) a vascular penneability enhancing factor can be generated in vitro in C1INH-depleted, C2-deficient plasma, but not from C1INH-depleted, contact system-deficient plasma: this factor was identified by sequence analysis as bradykinin; (2) bradykinin can be detected in the plasma of HAE patients during attacks of angioedema: (3) in several members of one family, expression of a C1INH variant that inhibits contact system proteases but has defective inhibition of C1r and C1s does not result in HAE; (4) C1INH-deficient (C1INH(-/-)) mice have a defect in vascular permeability that is suppressed by treatment with specific plasma kallikrein inhibitors and by bradykinin type 2 receptor (Bk2R) antagonists. and is eliminated in C1INH Bk2R(-/-) double-deficient mice. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 76 条
[1]  
BERRETTINI M, 1986, BLOOD, V68, P455
[2]   HUMAN C1BAR INHIBITOR - PRIMARY STRUCTURE, CDNA CLONING, AND CHROMOSOMAL LOCALIZATION [J].
BOCK, SC ;
SKRIVER, K ;
NIELSEN, E ;
THOGERSEN, HC ;
WIMAN, B ;
DONALDSON, VH ;
EDDY, RL ;
MARRINAN, J ;
RADZIEJEWSKA, E ;
HUBER, R ;
SHOWS, TB ;
MAGNUSSON, S .
BIOCHEMISTRY, 1986, 25 (15) :4292-4301
[3]  
BOOTH NA, 1987, BLOOD, V69, P1600
[4]   The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant [J].
Bos, IGA ;
Lubbers, YTP ;
Roem, D ;
Abrahams, JP ;
Hack, CE ;
Eldering, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :29463-29470
[5]   Structural and functional aspects of C1-Inhibitor [J].
Bos, IGA ;
Hack, CE ;
Abrahams, JP .
IMMUNOBIOLOGY, 2002, 205 (4-5) :518-533
[6]  
BUHLER R, 1995, BLOOD COAGUL FIBRIN, P223
[7]   Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor [J].
Colman, RW ;
Pixley, RA ;
Najamunnisa, S ;
Yan, WY ;
Wang, JY ;
Mazar, A ;
McCrae, KR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1481-1487
[8]   Contact system: A vascular biology modulator with anticoagulant, Profibrinolytic, antiadhesive, and proinflammatory attributes [J].
Colman, RW ;
Schmaier, AH .
BLOOD, 1997, 90 (10) :3819-3843
[9]  
COUTINHO M, 1994, J IMMUNOL, V153, P3648
[10]   Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired Cl-inhibitor deficiencies [J].
Cugno, M ;
Cicardi, M ;
Coppola, R ;
Agostoni, A .
IMMUNOPHARMACOLOGY, 1996, 33 (1-3) :361-364